

## Discovery Report

Patent: EVE-PAT-2026-001 | Organiq Sweden AB

## 1 - DISCOVERY

QUERY	TYPE 2 auto-scan: Similarity bridge: ceritinib rebastinib via KDR, FLT3, KIT +7 more
COMPOUND	CERITINIB
DISCOVERY SCORE	24.000
ENGINE	DISCOVERY_v1.2
CORPUS VERSION	v20260506-01
GENERATED	2026-05-14T03:00:01.048Z

## 2 - EVIDENCE

TARGETS	KDR, FLT3, KIT, NTRK1, LYN, RET, JAK2, FGR, NTRK2, SRC
PATHWAYS	—
EVIDENCE SCORE	0.00
STUDIES	0

## X-VAULT EVIDENCE SEAL

SYSTEM	BiohacksAI   XVAULT_v1
DISCOVERY ID	disc_T2_ceritinib_rebastinib_9ef647e6
EVENT HASH	0748bab72775541f...4e855d4d
CHAIN HASH	5dd1dd5b2397c0dd...ea27517f
PREV HASH	c0042510b065eb0c...0047922d
CORPUS VERSION	v20260506-01
CORPUS ROOT	6178ce3d1b9ff52e...d1c9a225
VAULT INDEX	3000
SEALED AT (UTC)	2026-05-14T03:00:01.073Z

## - VERIFICATION

This document is cryptographically sealed by the BiohacksAI X-Vault Evidence Engine. The discovery payload hash and corpus Merkle root can be independently verified.

Verify at: [eveverified.com/verify](https://eveverified.com/verify)

Verification fingerprint: 0748bab72775541f...4e855d4d

